Cann reiterated their buy rating on shares of Epizyme, Inc. (NASDAQ:EPZM) in a research report released on Thursday morning. They currently have a $26.00 price objective on the biopharmaceutical company’s stock.

“Epizyme’s loss per share of $0.63 was less than our estimated $(0.75). This primarily resulted from lower than estimated operating expense of $38.1 million compared to our estimated $44.5 million. Our outlook remains basically unchanged for 2018-2022.”,” the firm’s analyst commented.

A number of other research analysts have also issued reports on the company. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $20.00 target price on the stock in a report on Monday, October 16th. Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They set a buy rating and a $23.00 target price on the stock. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday, September 19th. Royal Bank Of Canada reaffirmed a buy rating and set a $20.00 target price on shares of Epizyme in a report on Friday, September 15th. Finally, BidaskClub raised Epizyme from a sell rating to a hold rating in a report on Thursday, August 24th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Epizyme presently has a consensus rating of Buy and an average target price of $22.67.

Shares of Epizyme (NASDAQ:EPZM) opened at $14.20 on Thursday.

Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. research analysts anticipate that Epizyme will post -2.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/06/epizyme-inc-epzm-receives-buy-rating-from-cann.html.

In other Epizyme news, Director David M. Mott bought 200,000 shares of the stock in a transaction on Monday, September 18th. The shares were bought at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $91,500. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the transaction, the insider now directly owns 22,228 shares in the company, valued at approximately $348,535.04. The disclosure for this sale can be found here. Insiders sold a total of 45,000 shares of company stock worth $733,950 in the last three months. 25.20% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. NEA Management Company LLC grew its stake in Epizyme by 3.2% during the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after acquiring an additional 200,000 shares in the last quarter. Palo Alto Investors LLC grew its stake in Epizyme by 18.9% during the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after acquiring an additional 907,245 shares in the last quarter. Vanguard Group Inc. grew its stake in Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after acquiring an additional 200,982 shares in the last quarter. State Street Corp grew its stake in Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after acquiring an additional 658,727 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in Epizyme during the 2nd quarter valued at about $9,726,000. 72.20% of the stock is currently owned by institutional investors.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.